Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds
- PMID: 33930524
- DOI: 10.1016/j.annonc.2021.04.016
Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds
Conflict of interest statement
Disclosure DGJR; Consultancy fee from Bayer, honorarium from Springer Media B.V., Travel fee from Sanofi. RdW; Consultancy fees and honoraria from Sanofi-Genzyme and Merck, consultancy fees from Astellas, Janssen, Bayer and Roche, Grant support (Institution); Sanofi-Genzyme and Bayer. SAJB has declared no conflicts of interest.
Comment on
-
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.Ann Oncol. 2021 Jul;32(7):896-905. doi: 10.1016/j.annonc.2021.03.205. Epub 2021 Apr 6. Ann Oncol. 2021. PMID: 33836265 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
